The NEPHROCHECK® Test biomarkers (TIMP- 2 and IGFBP7) that indicate kidney stress in advance of acute kidney injury (AKI) have been included in the “Guidelines for Perioperative Care in Cardiac Surgery” which were published by the ERAS® (Enhanced Recovery After Surgery) Cardiac Society, an international group of leading heart surgeons, anesthesiologists and critical care specialists.
Marcy l'Étoile, April 24, 2019 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2019.
Please be advised that bioMérieux, Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Friday, April 19, 2019 in observance of the upcoming holiday. We encourage you to place orders with these dates in mind.
The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitro diagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes.
Baxter International Inc., a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI).
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc.
Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 21, 2019 in observance of Martin Luther King Jr. Day.
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units with the BACT/ALERT® VIRTUO® fully automated blood culture system.
Please be advised that all bioMérieux Inc. sites will be closed on December 24 - 25, 2018 and January 1, 2019 in observance of the upcoming holidays. We encourage you to place your orders with these dates in mind to ensure you receive products as needed.
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY® Pneumonia Panel plus. The BIOFIRE® FILMARRAY® Pneumonia Panels aid in the diagnosis of lower respiratory tract infections.
